CTX-130
CRISPR Therapeutics AG
['lymsm', 'cobalt-lym', 'lymphoma']
congress #eha2022 | swaminathan iyer presented first-in-human results of cobalt-lym phase i trial of ctx130 in heavily pretreated patients with r/r tcl. n=18, ctx130 showed encouraging efficacy and a tolerable safety profile across all dls #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm